Ophthalmology Science

Ophthalmology Science is an online, peer-reviewed, gold open access journal published by Elsevier on behalf of the American Academy of Ophthalmology, founded in 2021 and devoted to pre-clinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology informatics and clinical science, with a 2025 Journal Impact Factor of 5.0.《眼科学》（Ophthalmology Science）是（Elsevier）代表美国眼科学会（AAO）出版的在线同行评审、金色开放获取期刊，2021 年创刊，聚焦临床前开发、1 期与 2 期临床试验、实验室研究、眼科信息学与临床科学，2025 年期刊影响因子为 5.0。

Scope

• The journal focuses on publishing pre-clinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology informatics and clinical science.本刊聚焦临床前开发、1 期与 2 期临床试验、实验室研究、眼科信息学与临床科学。
• It features studies that are preclinically focused, including translational research, basic science, early-phase clinical trial reports, and bioinformatics and artificial intelligence applications in ophthalmology.刊物以临床前导向的研究为特色，包括转化研究、基础科学、早期临床试验报告，以及眼科生物信息学与人工智能应用。
• Fields represented on its editorial board include retinal diseases and imaging, glaucoma, cornea, ocular oncology, uveitis, paediatric ophthalmology and ophthalmic epidemiology.编辑部覆盖的领域包括视网膜疾病与成像、青光眼、角膜、眼部肿瘤、葡萄膜炎、小儿眼科与眼科流行病学。
• Submission types include manuscripts, AAO meeting papers, correspondence, editorials, systematic reviews and meta-analyses, translational science reviews and invited reports.投稿类型包括普通稿件、（AAO）会议论文、通讯、社论、系统综述与荟萃分析、转化科学综述以及特邀报告。
• The journal holds the right of first refusal for papers presented at the annual meeting of the American Academy of Ophthalmology.本刊对美国眼科学会年会报告的论文拥有优先取舍权。
• As the fourth journal in the Academy's Ophthalmology family and its first open access journal, it complements the clinical focus of Ophthalmology, Ophthalmology Retina and Ophthalmology Glaucoma.作为美国眼科学会眼科系列期刊的第四种刊物与首种开放获取期刊，本刊与专注临床的（Ophthalmology）、（Ophthalmology Retina）和（Ophthalmology Glaucoma）形成互补。

History

• The American Academy of Ophthalmology announced the journal in July 2020 and launched it in the first quarter of 2021, with the inaugural issue published in March 2021.美国眼科学会于 2020 年 7 月宣布创办该刊，2021 年第一季度正式推出，创刊号于 2021 年 3 月出版。
• It was conceived as the Academy's first gold open access journal, available online only and supported by article publishing charges rather than subscriptions.该刊被定位为美国眼科学会首种金色开放获取期刊，仅在线出版，以文章出版费而非订阅费支持运营。
• The journal launched as a quarterly, moved to bimonthly publication with volume 4 in 2024, and has published monthly since volume 6 in 2026.刊物创刊时为季刊，2024 年第 4 卷起改为双月刊，2026 年第 6 卷起为月刊。
• Copyright in published articles is transferred to the American Academy of Ophthalmology, the default licence is CC BY-NC-ND, and a CC BY licence is available on request for funders that require it.论文版权转让给美国眼科学会，默认许可为（CC BY-NC-ND），如资助方要求可改用（CC BY）许可。
• The article publishing charge is USD 2,750 excluding taxes, with a discount for Academy members, and the journal is indexed in Scopus, ESCI (Web of Science), PubMed Central and DOAJ.文章出版费为 2,750 美元（不含税），学会会员可享折扣，本刊被（Scopus）、（ESCI）（Web of Science）、（PubMed Central）与（DOAJ）收录。
• The 2025 Journal Impact Factor is 5.0, up from 4.6 in 2024, the CiteScore is 7.0, and the acceptance rate is 31 percent.2025 年期刊影响因子为 5.0，高于 2024 年的 4.6，（CiteScore）为 7.0，录用率为 31%。

Editors

• The inaugural editor-in-chief is Dr. Emily Y. Chew, MD, of the National Eye Institute in Bethesda, Maryland, United States, whose work covers clinical trials and epidemiologic studies in retinovascular diseases.创刊主编为美国马里兰州贝塞斯达美国国家眼科研究所（NEI）的（Emily Y. Chew）医学博士，研究方向为视网膜血管疾病的临床试验与流行病学研究。
• Eleven associate editors support her: Rajendra S. Apte and Aaron Yuntai Lee of Washington University in St Louis, Mark Bullimore of the University of Houston, Matilda Chan and Jay Stewart of the University of California San Francisco, Anne Hanneken of Scripps Research, Thomas Johnson III of Johns Hopkins University, SriniVas Sadda and David Sarraf of the University of California Los Angeles, Joel Schuman of Wills Eye Hospital, and Susan Vitale of the National Eye Institute.十一位副主编协助其工作：（Rajendra S. Apte）与（Aaron Yuntai Lee）任职于圣路易斯华盛顿大学，（Mark Bullimore）任职于休斯敦大学，（Matilda Chan）与（Jay Stewart）任职于加利福尼亚大学旧金山分校，（Anne Hanneken）任职于（Scripps Research），（Thomas Johnson III）任职于约翰斯·霍普金斯大学，（SriniVas Sadda）与（David Sarraf）任职于加利福尼亚大学洛杉矶分校，（Joel Schuman）任职于（Wills Eye Hospital），（Susan Vitale）任职于美国国家眼科研究所。
• The editorial board lists about twenty members, including Lois E. H. Smith and Lucia Sobrin of Harvard Medical School, Bennie H. Jeng of the University of Pennsylvania, Martine J. Jager of Leiden University in the Netherlands, Daniel Ting of Duke-NUS Medical School in Singapore and Benjamin Xu of the University of Southern California.编委会约有二十位成员，包括哈佛医学院的（Lois Smith）与（Lucia Sobrin）、宾夕法尼亚大学的（Bennie Jeng）、荷兰莱顿大学的（Martine Jager）、新加坡（Duke-NUS）医学院的（Daniel Ting）与南加利福尼亚大学的（Benjamin Xu）。
• A senior social media editor and social media editors, among them Edmund Tsui of the University of California Los Angeles, complement the board, and the editorial staff includes executive editor May Piotrowski.编委会之外设有资深社交媒体编辑与社交媒体编辑，包括加利福尼亚大学洛杉矶分校的（Edmund Tsui），编辑部工作人员包括执行编辑（May Piotrowski）。
• Peer review is single anonymous, and in the most recent reporting period the journal took a median of 12 days from submission to first decision, 55 days to a decision after review and 134 days to acceptance, with 8 days from acceptance to online publication.同行评审为单匿名方式，最新报告期内从投稿到首次决定的中位时间为 12 天，评审后决定为 55 天，录用为 134 天，接受到在线发表为 8 天。